Featured News

At UEGW, researchers from Takeda, the University of Sheffield, Columbia University, Coeliac UK, and CDF virtually presented a study entitled, Experiences of a gluten-free diet in patients with celiac disease: a multi-national survey.

CDF Proud Sponsor Nestlé offers more than 25 gluten-free options to ensure consumers have delicious choices regardless of their dietary needs.

The findings of the Research Opportunities in Celiac Disease Consensus Workshop, sponsored by the CDF, were published as a Research Roadmap for NIH.

To secure increased federal investments in celiac disease research, a group of CDF advocates began discussions in 2019 with key Members of Congress and the NIH.

It’s team-forming time! Looking for something fun to do with your friends and family, no matter where they are across the nation? Learn more about our Virtual Turkey Trot Cross-Country Challenge and how joining or creating a team can expand your fundraising and impact to accelerate celiac disease research for a cure.

On August 24, Rep. Betty McCollum launched the bipartisan Celiac Disease Caucus. We look forward to continuing to work with Rep. McCollum and the Caucus to support innovative research and advance legislation that will ease the suffering of celiac patients.

Please take one minute to email your Members of Congress to make it easier and safer for those with celiac disease to purchase food items by requiring labels to list the presence of barley and rye, in addition to wheat.

There are more exciting opportunities than ever before to participate in celiac disease clinical trials. Researchers are making groundbreaking progress in the race for better treatments with promising new drug candidates.

The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.

Periodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.